Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novartis
Biotech
AHA: Novartis’ Lp(a) drug shows zero benefit
Novartis reported a total absence of efficacy that could intensify questions about upcoming readouts from Amgen and Eli Lilly.
Nick Paul Taylor
Nov 7, 2026 9:50am
Novartis scraps $800M BioArctic brain collab after barely a year
Nov 3, 2026 4:53am
Fierce Pharma
Novartis refreshes myelofibrosis bid as Geron flops in ph. 3
Oct 29, 2026 8:15am
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
Novartis CEO keeps faith in Avidity despite $1.9B hit from fail
Oct 27, 2026 3:48am
Vanda pauses social anxiety program after failing phase 3 trial
Oct 15, 2026 2:25am
